Gitnux/Report 2026

Dental Bone Graft Industry Statistics

201Statistics
64Sources
12Sections
38mRead
Dental Bone Graft Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The dental bone graft industry at a glance

The global dental bone grafts and substitutes market was valued at $901.1 million in 2025 and is forecast to reach $1.78 billion by 2033, driven by implant procedures and regenerative dentistry.

$901.1M[16]
Global market size, 2025
9.1%[16]
Forecast CAGR, 2026–2033
38.3%[16]
North America share, 2025
$2.33B[27]
Biomaterials market size, 2025
Market size
Grand View Research estimates the global dental bone grafts and substitutes market at $901.1 million in 2025 and $973.1 million in 2026. A narrower dental bone graft substitutes definition produces a 2025 estimate of $328.14 million from Fortune Business Insights.[16][50]
Forecast & CAGR
Grand View Research forecasts growth from $973.1 million in 2026 to $1.7849 billion in 2033, representing a 9.1% CAGR. Fortune Business Insights forecasts the substitutes-only market to reach $612.03 million by 2034 at a 7.23% CAGR.[16][50]
Market share & regions
North America accounted for 38.3% of global dental bone grafts and substitutes revenue in 2025 according to Grand View Research. In the narrower substitutes market, Fortune Business Insights reports a 47.93% North American share in 2025.[16][50]
Segmentation
Products are commonly segmented by material into allografts, xenografts and synthetic grafts; Fortune Business Insights additionally identifies demineralized bone matrix. The market is also segmented by form, including granules and putty, and by end user, including solo practices and dental service organization or group practices.[16][50]
Key players & concentration
iData Research identifies Geistlich Pharma, Henry Schein and ZimVie as the three leading dental bone graft companies in 2026, with Geistlich ranked first in dental bone graft substitutes and barrier membranes. The source does not disclose a combined top-three percentage share.[27]
Pricing
Geistlich’s U.S. 2025 price list shows Bio-Oss xenograft pricing from $76 for 0.125 g to $1,112 for 5 g, while a 0.5 g product is listed at $167. These are list prices for graft material and do not represent the full patient charge, which can also include surgery, anesthesia and imaging.[51]
Trends, drivers & challenges
Market growth is linked to aging populations, tooth loss, periodontal disease and rising dental implant use, which increase demand for ridge augmentation, sinus elevation and extraction-site preservation. Key challenges include regulatory evidence requirements, clinical variability, biological-material sourcing and competition from lower-cost synthetic substitutes.[16][52]
Consumer behavior & competition
Demand is primarily clinician-led: dentists, periodontists and oral surgeons select materials based on defect type, handling, evidence, resorption characteristics and compatibility with implant treatment. Competition spans established regenerative brands and synthetic-material specialists; iData Research names Geistlich Pharma, Henry Schein and ZimVie among the leading companies in 2026.[27][16]
M&A
Recent consolidation includes Nobel Biocare’s acquisition of Versah, announced February 9, 2026, adding osseodensification and implant-site preparation products to its regenerative portfolio. Lifco also agreed to acquire a majority stake in Ethoss Regeneration, which reported approximately £5.4 million in sales for the year ended July 2025 and was expected to be consolidated in the first quarter of 2026.[53][54]
Regulation
In the United States, dental bone grafting material devices are generally Class II devices under 21 CFR 872.3930 and are subject to special controls and 510(k) requirements. FDA guidance covers materials such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, and collagen; products containing therapeutic biologics can fall under Class III requirements.[52]
Latest news
In August 2026, Isto Biologics announced the acquisition of NovaBone Products from Halma. NovaBone develops synthetic bioactive-glass bone grafts sold in more than 40 countries and used across dental, orthopedic, trauma and other surgical procedures.[55]

02 Ranking

Top 9 Companies in the Dental Bone Graft Industry

The leading companies in the dental bone graft industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Straumann Group leads Gitnux's 2026 dental bone graft ranking with an Overall score of 9.7, with operating margin 21.1% and revenue growth 4.1%. Zimmer Biomet is the runner-up at 9.1, backed by revenue growth 7.2% and operating margin 13.3%.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · #1 overall

    Straumann Group

    CH

    Ranked #1 · 9.7 · Dental implants, biomaterials and bone regeneration

    Why we picked it: Biomaterials portfolio includes Bio-Oss and Bio-Gide evidence and labeling for extraction-site and ridge defects.

    See in ranking ↓Visit straumann.com ↗

  2. #2 overall

    Zimmer Biomet

    US

    Ranked #2 · 9.1 · Dental and orthopedic biologics and bone grafts

    Why we picked it: Dental bone-graft substitutes supplier with R&D at 5.6% of revenue.

    See in ranking ↓Visit zimmerbiomet.com ↗

  3. #3 overall

    Envista

    US

    Ranked #3 · 9.0 · Dental implants and regenerative biomaterials

    Why we picked it: Regenerative biomaterials and Osteogenics offerings target implant and augmentation workflows.

    See in ranking ↓Visit envistaco.com ↗

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 9 companies in the dental bone graft industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Straumann Group

Dental implants, biomaterials and bone regeneration · CH

9.7
2

Zimmer Biomet

Dental and orthopedic biologics and bone grafts · US

9.1
3

Envista

Dental implants and regenerative biomaterials · US

9.0
4

BioHorizons Camlog Group

Dental implants, bone grafts and regenerative products

8.6
5

Dentsply Sirona

Dental consumables, implants and regenerative products · US

8.3
6

Regenity

Synthetic and collagen dental bone grafts · US

8.2
7

curasan

Synthetic dental bone substitutes · DE

8.2
8

Isto Biologics

Allograft and synthetic bone grafts · US

8.0
9

ZimVie

Dental implants and bone graft biomaterials · US

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 9 companies in the dental bone graft industry. In Dental Bone Graft Industry Statistics. Gitnux. https://gitnux.org/dental-bone-graft-industry-statistics/#top-companies

04 Statistics

Technology & Innovation

This section ties manufacturing and digital workflow change to measurable cycle-time and reported efficiency gains. It also logs adoption rates for AI/digital quality work, including 89% in 2020.

Automation in the dental bone graft industry

  • 2–3 weeks is the reported production time for personalized, viable BonoFill bone grafts using Bonus BioGroup’s disposable bioreactor system designed for automation, 2025, global.[1]
  • 50%+ production-efficiency gains were reported in the first year after dental laboratories implemented Oqton’s AI-driven manufacturing workflow, 2023, global dental-laboratory market.[2]

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[3]
  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[4]
  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[4]
  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[3]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[4]
  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[5]

Technology Adoption in the medical devices sector (sector benchmark)

  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[6]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[6]
  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[7]
  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[7]
  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[6]
  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[6]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[8]
  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[7]
  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[7]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[8]

Big Data in the medical devices sector (sector benchmark)

  • 49% of medtech companies reported struggling with untimely data in Model N’s 2025 survey of industry leaders.[9]
  • Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[10]
  • 45% was the average share of planned digital-enabler spending that medtech companies allocated to infrastructure, cloud enablement, architecture modernization, and AI and big data, globally, in 2021.[4]
  • Across medtech companies surveyed by Model N, nearly 70% already used or planned to use data and analytics in 2023.[9]
  • 80% of medtech companies planned to invest in infrastructure, cloud enablement, tech-architecture modernization, and AI and big data, based on a 2021 global survey.[4]
  • Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[6]

IoT in the medical devices sector (sector benchmark)

  • Among healthcare and medical-device IoT respondents, 31% planned to double the number of connected devices deployed in 2023.[11]
  • Among European healthcare industrial-ecosystem SMEs already using IoT, 21.4% used predictive maintenance for production assets in 2023.[6]
  • Among European healthcare industrial-ecosystem SMEs already using IoT, 22.3% used energy-saving devices such as smart lighting, HVAC or elevators in 2023.[6]
  • Among healthcare and medical-device IoT respondents, 9% had deployed between 10,001 and 100,000 connected devices in 2023.[12]
  • Across healthcare industrial-ecosystem SMEs in Europe, 20.4% already used Internet of Things technologies in 2023.[6]
  • Among healthcare and medical-device IoT respondents, 84% planned to increase their connected-device estate in 2023.[11]

05 Statistics

Data & Analytics

This section highlights data governance and traceability gaps in postmarket and clinical data handling. It also quantifies manual surveillance management: 51% of medical-device companies still do this in the 2025 benchmark.

Data Quality in the medical devices sector (sector benchmark)

  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[7]
  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[13]
  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[14]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[15]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[15]

Data Governance in the medical devices sector (sector benchmark)

  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[13]
  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[13]
  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[13]
  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[13]

06 Statistics

Strategy & Growth

This section anchors demand, applications, and forecast sizing. It reports socket preservation at 30.5% of global application share in 2025 and market growth from $973.1 million in 2026 to $1.7849 billion in 2033.

Growth in the dental bone graft industry

  • The global dental bone grafts and substitutes market was valued at $901.1 million in 2025.[16]
  • Dentsply Sirona’s End-Use and Equipment segment, which includes dental bone graft materials, grew 28.7% in 2021.[16]
  • The U.S. dental bone graft market is projected to grow at a 7.6% CAGR from 2026 to 2035.[17]
  • Socket preservation held 30.5% of the global dental bone grafts and substitutes market by application in 2025.[16]
  • The global dental bone grafts and substitutes market is projected to reach $1.7849 billion by 2033.[16]
  • The global dental bone grafts and substitutes market is estimated at $973.1 million for 2026.[16]

Differentiation in the dental bone graft industry

  • Ridge augmentation held a 44.0% share of the U.S. dental bone graft market by application in 2025.[17]
  • Socket preservation represented 9% of the U.S. dental bone grafts and substitutes market in 2025.[18]
  • Dental implant placement represented 42% of the U.S. dental bone grafts and substitutes market in 2025.[18]
  • Xenografts held a 48.2% share of the global dental bone graft market in 2024.[19]
  • The U.S. allograft dental bone graft segment is projected to achieve a 9.8% CAGR during the forecast period.[16]
  • Xenografts held a 38.0% share of the U.S. dental bone graft market in 2025.[17]

Mergers and acquisitions in the dental bone graft industry

  • Henry Schein acquired a 57% voting equity interest in Biotech Dental for preliminary consideration of $423 million in 2023.[20]
  • Xtant Medical had previously acquired nanOss distribution rights and intellectual property through its August 2023 acquisition of Surgalign assets.[20]
  • IsoTis sold its dental business to Keystone Dental for $7.4 million in 2006.[20]
  • Xtant Medical acquired RTI Surgical’s nanOss production operations for $2 million in cash plus contingent royalties in 2023.[20]

Strategic partnerships in the dental bone graft industry

  • IsoTis and Keystone Dental entered a five-year manufacturing and supply agreement in 2006.[20]
  • Celularity signed an exclusive commercialization agreement with BioCellgraft in December 2023 to manufacture private-label biomaterials for dental and oral healthcare.[20]
  • Bone Biologics acquired exclusive U.S. marketing, sales and distribution rights for OsStic under a five-year licensing agreement in 2025.[20]
  • Tutogen appointed Sulzer Calcitek as exclusive worldwide distributor of its dental xenograft bone tissue products in 2006.[20]
  • BioCellgraft was to distribute Celularity-manufactured advanced biomaterials under private-label brands for dental applications under the 2023 agreement.[20]

07 Statistics

People & Workforce

This section frames workforce cost and operating patterns using remote and hybrid benchmarks. It reports remote employees working 41.5 hours per week in 2023 and median hybrid salary of $135,000.

Remote Work in the medical devices sector (sector benchmark)

  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[21]
  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[21]
  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[21]
  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[21]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[21]
  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[21]
  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[21]
  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[21]

Employee Engagement in the medical devices sector (sector benchmark)

  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[22]
  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[22]
  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[22]
  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[22]

Change Management in the medical devices sector (sector benchmark)

  • Only 2% of surveyed medical device manufacturers rated their ability to estimate product-change costs as excellent, while 10% rated it poor.[23]
  • Among post-market medical device companies surveyed in 2023, 37% cited resistance to change efforts as a challenge to improving quality management processes.[14]
  • Among pre-market medical device companies surveyed in 2023, 18% cited lack of management buy-in as a challenge to improving quality management processes.[14]
  • Among pre-market medical device companies surveyed in 2023, 25% cited resistance to change efforts as a quality-management challenge.[14]
  • Among post-market medical device companies surveyed in 2023, 23% cited lack of management buy-in as a challenge to improving quality management processes.[14]

08 Statistics

Customer & Sales

This section quantifies patient acceptance and willingness to pay to avoid graft surgery. It reports 72% willing to pay extra for guided implant surgery and 54% accepting bone grafting in 2025.

Customer experience in the dental bone graft industry

  • 72% of patients in a 2025 survey were willing to pay extra for guided implant surgery to avoid bone-graft surgery.[24]
  • 54% of patients in a 2025 survey accepted undergoing bone grafting to enable dental implant placement.[24]
  • High professional and patient satisfaction with dental bone grafts was reported among 183 dentists surveyed in Sobral, Brazil.[25]
  • 72% of patients in a 2025 survey preferred bone harvesting from the retromolar region over other autologous sites.[24]
  • 67% of Austrian implant patients accepted additional costs for guided implant planning to avoid bone-graft surgery.[25]

09 Statistics

Marketing & Brand

This section captures clinician and periodontist interest signals tied to stem-cell-based grafting content. It also includes Geistlich launch planning of 20 regenerative products across more than 40 countries during 2026.

Marketing in the dental bone graft industry

  • 2 major regenerative-dentistry investments were reported for Geistlich: Bionnovation Biomedical in 2024 and ReOss in 2025.[26]
  • 20 new regenerative products were planned for launch across more than 40 countries by Geistlich during 2026, according to an industry market analysis.[27]

Digital marketing in the dental bone graft industry

  • 8.7% of U.S. periodontists surveyed were interested in receiving information about stem-cell-based bone grafting from other people or channels outside the listed education formats.[28]
  • 68.7% of 481 U.S. periodontists surveyed were interested in learning about stem-cell-based bone grafting through online continuing education.[28]
  • 3.7% of U.S. periodontists surveyed reported learning about stem-cell-based bone grafting through webinars, online tutorials or forums.[28]

Branding in the dental bone graft industry

  • 1st place was held by Geistlich Pharma in the global dental bone-graft substitute market in 2025, according to iData Research.[27]
  • 3rd place was held by ZimVie in the global dental bone-graft substitute market in 2025, according to iData Research.[27]
  • 2nd place was held by Henry Schein in the global dental bone-graft substitute market in 2025, according to iData Research.[26]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[29]
  • 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[30]
  • 50% of healthcare and pharmaceutical marketers had dedicated, growing budgets for creator or influencer marketing in 2026.[29]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[29]
  • 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[30]

10 Statistics

Operations & Execution

This section uses capacity and outsourcing market figures to set an operational context. It reports Granulab stated capacity of 350 kilograms per year for synthetic bone grafts at its Malaysian facility.

Quality management in the dental bone graft industry

  • 350 kilograms per year was Granulab’s stated production capacity for synthetic bone grafts at its Malaysian manufacturing facility.[31]
  • ISO 13485:2016 certification covered Granulab’s bone-substitute manufacturing facility in Shah Alam, Malaysia, according to SIRIM’s 2019 annual report.[31]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • $81.5 billion was the global medtech outsourcing market in 2023, covering contract development and manufacturing organizations (CDMOs).[32]
  • 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[32]
  • 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[32]
  • $26.3 billion was the U.S. medtech CDMO market in 2023, after 12.9% growth from 2022.[32]
  • $18.5 billion was the European medtech CDMO market in 2023.[32]

11 Statistics

Finance & Pricing

This section reports pricing ranges drawn from U.S. cost studies, separating autograft, alloplast, and xenograft. It also states global market growth inputs: 9.1% projected CAGR from 2026 to 2033.

Pricing strategy in the dental bone graft industry

  • $3,447 was the reported average autograft price in California, United States, in the cited dental bone-grafting cost study.[33]
  • $576–$1,375 was the reported U.S. average price range per alloplast dental bone graft in the 2024 cost study.[33]
  • $652–$1,575 was the reported U.S. average price range per allograft dental bone graft in the 2024 cost study.[33]
  • $2,161–$5,148 was the reported U.S. average price range per autograft dental bone graft in the 2024 cost study.[33]
  • $2,439 was the reported average autograft price in Alabama, United States, in the cited dental bone-grafting cost study.[33]

Cost reduction in the dental bone graft industry

  • $576–$1,375 was the U.S. average alloplast price range, compared with $2,161–$5,148 for an autograft, in the 2024 dental bone-grafting cost study.[33]
  • $549–$1,386 was the U.S. average xenograft price range, compared with $2,161–$5,148 for an autograft, in the 2024 dental bone-grafting cost study.[33]

Financial planning in the dental bone graft industry

  • 9.1% was the projected compound annual growth rate for the global dental bone grafts and substitutes market from 2026 to 2033.[16]
  • $1.7849 billion was the projected global dental bone grafts and substitutes market size for 2033.[16]
  • $973.1 million was the estimated global dental bone grafts and substitutes market size for 2026.[16]

12 Statistics

Product & Service

This section provides evidence and labeling datapoints, including defect geometry and clinical-study scale. It cites Geistlich Bio-Gide labeling evidence for vertical defect lengths up to 5.7 mm.

Product development in the dental bone graft industry

  • More than 10 million patients have been treated with Geistlich products, according to the company’s scientific-evidence page.[34]
  • 15 clinical studies involving 297 unique patients supported expanded labeling for Geistlich Bio-Gide in extraction-site and alveolar-ridge applications.[35]
  • Maxigen’s GingivAid Collagen Bone Graft received Taiwan TFDA approval in 2011, marking the product’s entry into the dental bone-graft medical-supplies market.[36]
  • More than 100 universities and leading surgeons have collaborated with Geistlich on developing and testing its dental biomaterials, according to the company’s scientific-evidence page.[34]
  • About 1,400 publications validate the efficacy of Geistlich Bio-Oss and Bio-Gide bone-regeneration products, according to Geistlich’s cited publication count.[34]

Product lifecycle in the dental bone graft industry

  • A randomized clinical trial enrolled 40 patients to compare new bone formation after 3 and 4 months of HA/β-TCP ridge-preservation treatment.[24]
  • Osteogenics reported 25 years of innovation and refinement in dental bone-grafting products on its company history page.[37]
  • FDA-reviewed animal testing assessed FG Bone Graft B and its predicate at 4, 8 and 12 weeks for new bone formation and material degradation.[35]
  • Geistlich Bio-Gide labeling evidence covered alveolar-ridge defects with average vertical defect lengths up to 5.7 mm and ridge widths up to 18 mm.[35]
  • The standardized FDA-reviewed alveolar defects measured 10 mm long, 5 mm wide and 5 mm deep.[35]

Value proposition in the dental bone graft industry

  • The global dental bone-grafts and substitutes market is projected to reach $1,784.9 million by 2033.[16]
  • The global dental bone-grafts and substitutes market was valued at $901.1 million in 2025, according to Grand View Research.[16]
  • North America held a 38.3% share of global dental bone-grafts and substitutes revenue in 2025.[16]
  • Xenografts accounted for 46.1% of the dental bone-grafts and substitutes market in 2025, according to Grand View Research.[16]
  • Socket preservation represented 30.5% of the dental bone-grafts and substitutes market by application in 2025.[16]

13 Statistics

Sustainability & Ethics

This section reports reported sustainability metrics tied to specific companies and years. It includes Straumann Group renewable electricity at 100% in 2024, including 100% at manufacturing sites.

Sustainability in the dental bone graft industry

  • 100% of Straumann Group manufacturing sites used renewable electricity in 2024 globally.[38]
  • More than 40 medical missions were conducted by Zimmer Biomet in 2024 for underserved patients worldwide.[39]
  • 58% of Zimmer Biomet’s in-scope global network was internally certified under its Zero Waste to Landfill initiative in 2024.[39]
  • Over 800 people were employed by Geistlich Pharma worldwide, whose portfolio includes dental bone-regeneration products.[34]
  • 13 Dentsply Sirona sites used renewable energy in 2024 globally.[40]

ESG in the dental bone graft industry

  • 45% was Dentsply Sirona’s reduction in absolute Scope 1 and 2 greenhouse-gas emissions from its 2019 baseline by 2024.[40]
  • 82 was Straumann Group’s employee-engagement score in 2024 globally.[38]
  • 26% was Dentsply Sirona’s reduction in absolute water withdrawal from its 2019 baseline by 2024.[40]
  • 39% of Straumann Group leadership positions were held by women in 2024 globally.[38]
  • 98% was Straumann Group’s global renewable-electricity usage in 2024, including 100% at manufacturing sites.[38]

Ethics in the dental bone graft industry

  • 9% was Dentsply Sirona’s increase in employee-resource-group membership in 2024.[40]
  • 100% of Zimmer Biomet required third-party compliance check-ins were completed in 2024.[39]
  • 16 languages were supported by Zimmer Biomet’s updated Code training course in 2024.[39]
  • 190 mentor-mentee pairs were matched by Zimmer Biomet in 2024 for leadership and career development.[39]
  • 100% of Zimmer Biomet team members and Board directors completed Code of Business Conduct and Ethics training in 2024 globally.[39]

CSR in the dental bone graft industry

  • Nearly 9,000 hours of community volunteering were contributed by Zimmer Biomet employees in 2024.[39]
  • 1.1 million more smiles were helped by Straumann Group in 2024 than in 2023, reaching 6.7 million.[38]
  • 400,000-plus dental professionals were trained by Straumann Group through educational efforts in 2024.[38]
  • Over $1 million was donated by Zimmer Biomet to charitable causes in 2024.[39]
  • 155 countries were represented among Dentsply Sirona clinical-education course participants in 2024.[40]

Circular economy in the dental bone graft industry

  • 100% recyclable packaging is Dentsply Sirona’s target for 2030 across its dental-products business.[40]
  • 63% was Straumann Group’s waste recycling rate in 2024 globally, down from 69% in 2023.[38]
  • 21 Zimmer Biomet sites were Zero Waste to Landfill certified in 2024.[39]
  • The majority of Straumann Group metal waste was recycled in 2024 across its production operations.[38]
  • 77% of Zimmer Biomet solid waste was diverted from landfills in 2024.[39]

Carbon footprint in the dental bone graft industry

  • 15% is Zimmer Biomet’s 2030 target for reducing Scope 3 emissions from purchased goods and services from its 2019 baseline.[39]
  • 55% is Zimmer Biomet’s 2030 target for reducing absolute Scope 1 and 2 emissions from its 2017 baseline.[39]
  • 8,781 tonnes CO2e were Straumann Group Scope 1 emissions in 2024.[38]
  • 19% was Straumann Group’s reduction in Scope 1 and 2 emissions from its 2021 base year by 2024.[38]
  • 1,432 tonnes CO2e were Straumann Group market-based Scope 2 emissions in 2024.[38]

15 Statistics

Globalization & Expansion

This section breaks out regional shares and distribution economics. It reports North America as 38.3% of 2025 global revenue and direct sales at 46% of the U.S. market in 2025.

Globalization in the dental bone graft industry

  • Europe accounted for 25.58% of the global dental bone graft substitute market in 2021.[48]
  • 52% of Envista’s sales came from North America, 22% from Western Europe, 21% from emerging markets and 5% from other developed markets in 2024.[49]
  • North America accounted for 38.3% of global dental bone grafts and substitutes revenue in 2025.[16]
  • Asia-Pacific is projected to record a 10.9% CAGR in dental bone grafts and substitutes from 2026 to 2033.[16]
  • The U.S. represented 42.0% of the North American dental bone graft market in 2025.[17]

Supplier management in the dental bone graft industry

  • Xtant Medical paid $2 million in cash plus a low-single-digit royalty on future sales to acquire RTI’s nanOss synthetic bone graft production operations in 2023.[20]
  • Xtant Medical assumed the lease for RTI Surgical’s nanOss production facility in Greenville, North Carolina, as part of the 2023 transaction.[20]
  • The nanOss royalty arrangement covered next-generation product sales made before October 23, 2028.[20]
  • A five-year manufacturing and supply agreement accompanied IsoTis’s 2006 sale of its dental business and bone graft substitute portfolio to Keystone Dental.[20]

Stakeholder management in the dental bone graft industry

  • Hospitals are projected to achieve a 10.2% CAGR in dental bone grafts and substitutes during the forecast period.[16]
  • Dental clinics represented 70.1% of global dental bone grafts and substitutes end-use revenue in 2025.[16]

Distribution channels in the dental bone graft industry

  • Direct sales accounted for 46% of the U.S. dental bone grafts and substitutes market in 2025.[18]
  • Dental distributors accounted for 34% of the U.S. dental bone grafts and substitutes market in 2025.[18]
  • Online procurement platforms represented 8% of the U.S. dental bone grafts and substitutes market in 2025.[18]
  • Online procurement platforms are projected to grow at an 11.2% CAGR in the U.S. dental bone grafts and substitutes market.[18]
  • A 2025 licensing agreement gave Bone Biologics exclusive U.S. marketing, sales and distribution rights for OsStic for an initial five-year term.[20]

Key questions about the dental bone graft industry

What is the global market size for dental bone grafts and substitutes in 2025 and 2026?
The market was valued at $901.1 million in 2025 and estimated at $973.1 million for 2026.
How fast is the market expected to grow from 2026 to 2033?
Grand View Research forecasts growth from $973.1 million in 2026 to $1.7849 billion in 2033, at a 9.1% CAGR.
Which companies lead the dental bone graft industry?
Straumann Group leads Gitnux's 2026 dental bone graft ranking with an Overall score of 9.7, with operating margin 21.1% and revenue growth 4.1%. Zimmer Biomet is the runner-up at 9.1, backed by revenue growth 7.2% and operating margin 13.3%.
What technology shifts are being reported in medtech manufacturing and quality systems?
In 2020, 87% of medtech and IVD professionals said their company implemented or planned AI/digital solutions in regulatory or quality-management systems. In 2022, 64% of medtech manufacturing executives highly prioritized digitizing manufacturing.
How is the market structured by end user and regional share?
Dental clinics represented 70.1% of global end-use revenue in 2025, and North America accounted for 38.3% of global revenue in 2025.
What regulatory frame applies to dental bone grafting material devices in the U.S.?
In the United States, dental bone grafting material devices are generally Class II under 21 CFR 872.3930 with special controls and 510(k) requirements; materials with therapeutic biologics can fall under Class III.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Dental Bone Graft Industry Statistics. Gitnux. https://gitnux.org/dental-bone-graft-industry-statistics
MLA
Samuel Norberg. "Dental Bone Graft Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/dental-bone-graft-industry-statistics.
Chicago
Samuel Norberg. 2026. "Dental Bone Graft Industry Statistics." Gitnux. https://gitnux.org/dental-bone-graft-industry-statistics.

Sources & references

64 sources cited across this report

  1. bonus-bio.com
  2. investor.3dsystems.com
  3. nsf.org
  4. bcg.com
  5. mastercontrol.com
  6. monitor-industrial-ecosystems.ec.europa.eu
  7. veeva.com
  8. pages.awscloud.com
  9. modeln.com
  10. www-statista-com.libproxy.pcc.edu
  11. ashb.com
  12. eseye.com
  13. sana-suisse-med.ch
  14. blog.greenlight.guru
  15. distillersr.com
  16. grandviewresearch.com
  17. emergenresearch.com
  18. towardshealthcare.com
  19. databridgemarketresearch.com
  20. sec.gov
  21. mddionline.com
  22. cultureamp.com
  23. resources.sw.siemens.com
  24. pmc.ncbi.nlm.nih.gov
  25. pubmed.ncbi.nlm.nih.gov
  26. globenewswire.com
  27. idataresearch.com
  28. aap.onlinelibrary.wiley.com
  29. brand-news.it
  30. media.sproutsocial.com
  31. sirim.my
  32. alirahealth.com
  33. carecredit.com
  34. geistlich.com
  35. accessdata.fda.gov
  36. financialfilings.com
  37. osteogenics.com
  38. straumann.com
  39. investor.zimmerbiomet.com
  40. dentsplysirona.com
  41. greenlight.guru
  42. cognition.us
  43. runsafesecurity.com
  44. deloitte.com
  45. mdic.org
  46. dennemeyer.com
  47. 2bridge.partners
  48. techsciresearch.com
  49. archive.fast-edgar.com
  50. fortunebusinessinsights.com
  51. scribd.com
  52. fda.gov
  53. nobelbiocare.com
  54. inderes.dk
  55. novabone.com
  56. envistaco.com
  57. biohorizons.com
  58. regenity.com
  59. curasan.com
  60. istobiologics.com
  61. zimvie.com
  62. who.int
  63. ada.org
  64. law.cornell.edu